日本の微生物検査装置市場:メーカーシェア、市場予測、技術、競争戦略

◆英語タイトル:2014-2018 Japanese Automated Microbiology Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies -Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics
◆発行会社/調査会社:Venture Planning Group
◆商品コード:VPAM7058-11
◆発行日:2014年11月11日
◆調査対象地域:日本
◆産業分野:医療機器(診断・検査装置)
◆ページ数:421
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Local PDFUSD8,850 ⇒換算¥955,800見積依頼/購入/質問フォーム
Global PDFUSD19,500 ⇒換算¥2,106,000見積依頼/購入/質問フォーム
DataPackUSD5,700 ⇒換算¥615,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVenture Planning Group社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
Venture Planning Group社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[日本の微生物検査装置市場:メーカーシェア、市場予測、技術、競争戦略]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Complete report $8,850.  DataPack (test volumes, sales forecasts, supplier shares) $5,700.

Japanese Automated Microbiology Market 2014” is a new analysis of major business opportunities emerging in the Japanese automated microbiology market during the next five years.  The report examines key trends, reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
 
Rationale

The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology.  The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests.

The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems.  The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies.  The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans.  Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.

The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.

This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding Japanese microbiology market, in evaluating emerging opportunities and developing effective business strategies.  

Market Segmentation Analysis

- Sales and market shares for major suppliers by individual test.

- Volume and sales forecasts for over 100 infectious disease
assays by individual test:

- Test volume estimates by method (molecular, serology/immunodiagnostics,
culture/microscopy).

- Review of the market dynamics, trends, structure, size, growth
and major suppliers.

Specimen Types

- Urine
- Sterile Fluids: Blood, Serum, CSF
- Throat Swabs, Respiratory Secretions
- Genital Secretions
- Stool
- Abscess/Wound
- Sputum
- Saliva

Applications

- Microbial Identification
- Antibiotic Susceptibility
- Urine Screening
- Blood Cultures

Review of Major Automated Systems

- Review of major automated molecular diagnostic, multipurpose, specialized,
microbial identification, antibiotic susceptibility, blood culture, urine screening,
and immunodiagnostic analyzers.

- The report profiles analyzers manufactured by Abbott, Alifax, Anagen,
BD, Beckman Coulter/Danaher, Biochem, Biolog, bioMerieux, Bio-Rad,
Biotrol, Cepheid, Curetis, GenMark, Hologic/Gen-Probe, HTG, Iris, J&J,
Labsystems, Life Technologies, MiDI, Olympus, Qiagen, Roche, Siemens,
Sy-Lab, Sysmex, Tecan, Thermo Fisher, Tosoh.

Infectious Diseases Analyzed in the Report

AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter,
Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium,
Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea,
Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme,
Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps,
Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.

Technology Review

- Assessment of molecular diagnostic, monoclonal antibody,
immunoassay, and other technologies and their potential
applications for the microbiology market.

- Global listings of companies developing or marketing microbiology
products by individual test.

Competitive Assessments

- Strategic assessments of major suppliers and emerging market entrants,
including their sales, product portfolios, marketing tactics, collaborative
arrangements and new products in R&D.

- The companies analyzed in the report include Abbott, Affymetrix, Agilent Technologies,
Arca/Nuvelo, Beckman Coulter/Danaher, Becton Dickinson, Biokit, bioMerieux,
Bio-Rad, Biotest, Caliper, Cepheid, Decode, Diadexus, Diamedix, DiaSorin, Eiken Chemical, Enzo Biochem, Exact Sciences, Fujirebio/Innogenetics, Hologic/Gen-Probe, Illumina, ID Biomedical/GSK, Kreatech, Li-Cor Biosciences, Life Technology, Lonza, Monogram Biosciences, Myriad Genetics, Nanogen/Elitech, Novartis Diagnostics/Grifols, Orchid CellMark, Ortho-Clinical Diagnostics, Proteome Sciences, Qiagen, Roche, Scienion, Sequenom, SeraCare, Siemens, Sierra Molecular, Shimadzu, Takara Bio, Tecan, Thermo Fisher, Wallac/PE, Wako.

Opportunities and Strategic Recommendations

- Emerging opportunities for new analyzers, reagents kits,
IT and other products with significant market appeal during the next five years.

- Design criteria for decentralized testing products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Contains 421 pages and 79 tables

*** レポート目次(コンテンツ)***

※目次は下記のURLをご参照ください。

http://www.vpgcorp.com/webfiles/MICROBIOLOGY/TOC%20JapaneseAutomatedMicrobiologyMarketMDMI.pdf



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(VPAM7058-11 )"日本の微生物検査装置市場:メーカーシェア、市場予測、技術、競争戦略" (英文:2014-2018 Japanese Automated Microbiology Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies -Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics)はVenture Planning Group社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。